secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007007
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports positive ACR-368 Phase 2b data in serous EC; ACR-2316 shows tumor shrinkage in Phase 1
--------------------------------------------------------------------------------

- ACR-368 Phase 2b: 39% ORR overall; in serous EC ≤2 prior lines, cORR 52% (N=23) and 67% in BM+ (N=12). Arm 3 expanding to EU, enrollment complete Q4 2026.
- ACR-2316 Phase 1: 33 patients dosed; tumor shrinkage in 9/20 evaluable; confirmed PR in EC, unconfirmed PRs in SCLC and sqNSCLC. Two weekly schedules set.
- ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as development candidate; IND submission planned for Q4 2026.
- Preliminary cash, cash equivalents and investments ~$119M as of Dec 31, 2025, expected to fund operations into Q2 2027.
- Phase 3 confirmatory protocol for ACR-368 + anti-PD-1 submitted to FDA Nov 2025; global trial readiness expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526007007/0001193125-26-007007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526007007/acrv-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer